

Hege Sagstuen Haugnes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7091399/publications.pdf>

Version: 2024-02-01

27
papers

296
citations

933447

10
h-index

940533

16
g-index

28
all docs

28
docs citations

28
times ranked

407
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. <i>Journal of Clinical Oncology</i> , 2018, 36, 3381-3387. | 1.6 | 49 |
| 2 | Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort. <i>Journal of Clinical Oncology</i> , 2021, 39, 3561-3573. | 1.6 | 46 |
| 3 | Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group. <i>European Urology Oncology</i> , 2020, 3, 382-389. | 5.4 | 28 |
| 4 | Inflammatory serum markers and risk and severity of prostate cancer: The PROCA-life study. <i>International Journal of Cancer</i> , 2020, 147, 84-92. | 5.1 | 26 |
| 5 | Cancer therapy and risk of congenital malformations in children fathered by men treated for testicular germ-cell cancer: A nationwide register study. <i>PLoS Medicine</i> , 2019, 16, e1002816. | 8.4 | 17 |
| 6 | Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols. <i>Acta Oncologica</i> , 2015, 54, 493-499. | 1.8 | 13 |
| 7 | Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 891-905. | 2.4 | 12 |
| 8 | Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes. <i>Acta Oncologica</i> , 2019, 58, 690-699. | 1.8 | 11 |
| 9 | Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group. <i>European Urology Oncology</i> , 2022, 5, 235-243. | 5.4 | 11 |
| 10 | Bilateral testicular cancer within two prospective, population-based SWENOTECA protocols in clinical stage I nonseminoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 4508-4508. | 1.6 | 11 |
| 11 | FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry. <i>Journal of Clinical Oncology</i> , 2017, 35, 4521-4521. | 1.6 | 11 |
| 12 | Testosterone (T), luteinizing hormone (LH), and follicle stimulating hormone (FSH) levels in testicular cancer survivors (TCSs) 11 and 19 years after orchiectomy. <i>Journal of Clinical Oncology</i> , 2013, 31, 4562-4562. | 1.6 | 11 |
| 13 | Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000-2014: A Population-based Cohort Study. <i>European Urology Open Science</i> , 2021, 32, 19-27. | 0.4 | 10 |
| 14 | Management of clinical stage I seminomatous testicular cancer: A report from SWENOTECA. <i>Journal of Clinical Oncology</i> , 2014, 32, 4508-4508. | 1.6 | 9 |
| 15 | A controlled study of risk factors for disease and current problems in long-term testicular cancer survivors. <i>Journal of Cancer Survivorship</i> , 2010, 4, 256-265. | 2.9 | 8 |
| 16 | Mortality and Second Cancer Incidence After Treatment for Testicular Cancer: Psychosocial Health and Lifestyle Are Modifiable Prognostic Factors. <i>Journal of Clinical Oncology</i> , 2022, 40, 2588-2599. | 1.6 | 7 |
| 17 | Expression of miR-24-1-5p in Tumor Tissue Influences Prostate Cancer Recurrence: The PROCA-life Study. <i>Cancers</i> , 2022, 14, 1142. | 3.7 | 4 |
| 18 | One course of adjuvant BEP in clinical stage I, nonseminoma: Mature and expanded results from the SWENOTECA group. <i>Journal of Clinical Oncology</i> , 2013, 31, 4553-4553. | 1.6 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Fatigue in relation to treatment and gonadal function in a population-based sample of 796 testicular cancer survivors 12 and 19 years after treatment.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4564-4564. | 1.6 | 2 |
| 20 | Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4551-4551. | 1.6 | 2 |
| 21 | The ABC-study: A randomized phase III study comparing one course of adjuvant bleomycin, etoposide, and cisplatin (BEP) and one course of carboplatin AUC7 in clinical stage I seminomatous testicular cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4593-TPS4593. | 1.6 | 2 |
| 22 | Impact of long-term serum platinum on neuro- and ototoxicity, cardiovascular disease, and hypogonadism in testicular cancer survivors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4518-4518. | 1.6 | 1 |
| 23 | Cardiovascular risk and the impact of self-reported physical activity in long-term testicular cancer survivors: A longitudinal study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16048-e16048. | 1.6 | 1 |
| 24 | Longitudinal serum testosterone levels (T) in long-term testicular cancer survivors (TCSs) in relation to testicular cancer (TC) treatment, aging, and TC diagnosis itself.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4637-4637. | 1.6 | 0 |
| 25 | Audiograms and hearing loss before and after cisplatin-based chemotherapy (CBCT) in testicular cancer survivors (TCS).. <i>Journal of Clinical Oncology</i> , 2017, 35, e16047-e16047. | 1.6 | 0 |
| 26 | Long-term platinum (Pt) change and its associations with cisplatin-related late effects in testicular cancer survivors (TCSs).. <i>Journal of Clinical Oncology</i> , 2018, 36, e22067-e22067. | 1.6 | 0 |
| 27 | PD19-06â€fLOCATION AND HISTOLOGY OF RETROPERITONEAL METASTASES IN POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOR NON-SEMINOMA GERM CELL TUMOUR. <i>Journal of Urology</i> , 2020, 203, e384. | 0.4 | 0 |